State Street SPDR S&P Biotech ETF (XBI)
Market Price (6/29/2026): $155.03
State Street SPDR S&P Biotech ETF (XBI)
Market Price (6/29/2026): $155.03
Key Takeaways
- XBI has returned +27.4% YTD vs +7.2% for SPY; +87.9% over the past 12 months (SPY +19.6%). details →
- Priced in gold, XBI has returned -11.1% over the past 3 years, vs +89.1% in dollars — its dollar gains have lagged gold. details →
- Over the past month, XBI has seen net inflows of +$1.08B (+13.0% of assets). details →
- Only 31% of XBI's portfolio (by weight) is currently profitable, vs 98% for SPY. details →
- Risk-adjusted returns trail SPY: 3-year Sharpe ratio of 0.6 vs 1.2. details →
Asset Allocation with XBI
Valuation & Yield
| Forward [4,5] | Now | Historical (CYE & TTM) | |||||
|---|---|---|---|---|---|---|---|
| 6/30/27 | 6/29/26 | 2025 | 2024 | 2023 | 2022 | 2021 | |
| Share Price CYE | $155.38 | $121.93 | $89.72 | $88.83 | $82.56 | $111.36 | |
| Dividend/Share TTM | $0.43 | $0.45 | $0.13 | $0.02 | $0.00 | $0.04 | |
Valuation [1] | |||||||
| P/S | 7.08 | 8.27 | 6.66 | 7.16 | 7.75 | 4.58 | 18.18 |
| P/E | 64.40 | 40.59 | 36.88 | 83.91 | 70.75 | 91.26 | |
| P/E (Non-GAAP) [2] | 46.97 | 56.24 | 41.40 | 33.45 | 82.29 | 55.67 | 67.22 |
| P/FCF | — | — | — | — | — | — | |
Yields TTM | |||||||
| Earnings Yield | 2.13% | 1.55% | 2.46% | 2.71% | 1.19% | 1.41% | 1.10% |
| Dividend Yield | 0.28% | 0.28% | 0.37% | 0.15% | 0.02% | 0.00% | 0.04% |
| Total Yield (TY) | 2.41% | 1.83% | 2.83% | 2.86% | 1.21% | 1.41% | 1.13% |
Risk Premium [3] | |||||||
| Risk Free Rate (Rf) | 4.40% | 4.40% | 4.18% | 4.58% | 3.88% | 3.88% | 1.52% |
| Risk Prem. (TY - Rf) | -1.99% | -2.57% | -1.35% | -1.72% | -2.67% | -2.47% | -0.39% |
Growth Rates [6] | |||||||
| Sales Growth | 18.2% | -2.7% | 25.0% | 15.2% | -10.4% | 6.0% | |
| Earnings Growth [7] | |||||||
[1] P/E uses the aggregate method over profitable constituents; P/FCF aggregates net free cash flow across all constituents (negative-FCF names reduce it); P/S uses all constituents. Ratios reflect current ETF holdings at current weights. P/FCF has no Forward column (no analyst FCF estimate).
[2] P/E (Non-GAAP) uses analyst consensus net income (adjusted basis) for all periods. The standard P/E row above uses GAAP net income.
[3] The premium above the risk free rate (US 10Y) offered by the investment. Negative premiums can indicate stretched valuations.
Show more
Top 20 Holdings for XBI
Total Weights Top 5: 6.8% | Top 10: 13.0% | Top 20: 24.7%
| Ticker | Holding | ETF Weight | Sales Weight | Earnings Weight | Fwd P/S | Fwd P/E | Fwd Sales Growth | Fwd Earnings Growth |
|---|---|---|---|---|---|---|---|---|
| Total | 69.27% | 100.00% | 100.00% | 7.1 | 47.0 | +18.2% | +6.1% | |
| Top 20 | 14.58% | 6.58% | 0.00% | 18.7 | 541.9 | +45.0% | +823.0% | |
| APGE | Apogee Therapeutics | 1.57% | — | — | — | — | — | — |
| VKTX | Viking Therapeutics | 1.34% | — | — | — | — | — | — |
| TWST | Twist Bioscience | 1.32% | 1.05% | — | 12.2 | — | +17.0% | — |
| MRNA | Moderna | 1.29% | 1.28% | — | 11.6 | — | +19.5% | — |
| PRAX | Praxis Precision Medicines | 1.26% | — | — | — | — | — | — |
| ORKA | Oruka Therapeutics | 1.26% | — | — | — | — | — | — |
| KYMR | Kymera Therapeutics | 1.25% | 0.07% | — | 165.4 | — | -49.0% | — |
| RYTM | Rhythm Pharmaceuticals | 1.23% | 0.43% | — | 17.8 | — | +80.9% | — |
| CGON | CG Oncology | 1.23% | 0.01% | — | 123.8 | — | +689.4% | — |
| TVTX | Travere Therapeutics | 1.21% | 1.43% | — | 6.5 | 45.0 | +38.9% | +823.0% |
| MIRM | Mirum Pharmaceuticals | 1.20% | 1.12% | — | 9.8 | — | +20.4% | — |
| CYTK | Cytokinetics | 1.19% | 0.15% | — | 40.4 | — | +259.1% | — |
| NTRA | Natera | 1.18% | 0.95% | — | 12.1 | — | +18.9% | — |
| ROIV | Roivant Sciences | 1.17% | 0.00% | — | 114.8 | — | +635.1% | — |
| COGT | Cogent Biosciences | 1.17% | — | — | — | — | — | — |
| DNTH | Dianthus Therapeutics | 1.16% | 0.00% | — | 3,044.2 | — | +52.9% | — |
| SRRK | Scholar Rock | 1.16% | — | — | — | — | — | — |
| PCVX | Vaxcyte | 1.16% | — | — | — | — | — | — |
| RVMD | Revolution Medicines | 1.15% | — | — | — | — | — | — |
| QURE | uniQure | 1.15% | 0.08% | — | 38.6 | — | +535.8% | — |
[2] Forward P/S and P/E ratios use consensus sales and earnings for the 12 months ending 6/30/27. Individual constituent FY1 and FY2 consensus figures adjusted to align with 6/30/27.
[3] Forward Sales and Non-GAAP Earnings Growth are calculated as next fiscal year (FY2) consensus growth over current fiscal year (FY1) consensus. They are not derived from the forward P/S and P/E multiples shown.
Performance for XBI Top Holdings
| Ticker | Holding | Weight | Mkt Price6/28 | 1D Rtn | 1M Rtn | YTD Rtn | 1Y Rtn | 3Y Rtn | 5Y Rtn | 10Y Rtn |
|---|---|---|---|---|---|---|---|---|---|---|
| XBI | State Street SPDR S&P Biotech ETF | 100.00% | 155.38 | 0.0% | 13.7% | 27.4% | 87.9% | 89.1% | 15.1% | 191.2% |
| APGE | Apogee Therapeutics | 1.57% | 132.55 | 0.0% | 61.4% | 75.6% | 205.6% | |||
| VKTX | Viking Therapeutics | 1.34% | 38.04 | 0.0% | 16.2% | 8.1% | 43.4% | 143.5% | 517.5% | 2,919.0% |
| TWST | Twist Bioscience | 1.32% | 99.84 | 0.0% | 49.3% | 214.8% | 177.9% | 410.4% | -25.8% | |
| MRNA | Moderna | 1.29% | 67.27 | 0.0% | 42.6% | 128.1% | 147.7% | -44.9% | -71.3% | |
| PRAX | Praxis Precision Medicines | 1.26% | 327.79 | 0.0% | -6.3% | 11.2% | 662.3% | 1,816.9% | 9.8% | |
| ORKA | Oruka Therapeutics | 1.26% | 90.60 | 0.0% | 54.8% | 198.9% | 717.7% | 595.0% | 301.1% | -73.1% |
| KYMR | Kymera Therapeutics | 1.25% | 108.12 | 0.0% | 32.8% | 39.0% | 145.1% | 382.7% | 153.6% | |
| RYTM | Rhythm Pharmaceuticals | 1.23% | 109.84 | 0.0% | 24.4% | 2.6% | 75.1% | 557.3% | 445.4% | |
| CGON | CG Oncology | 1.23% | 71.96 | 0.0% | 15.5% | 73.3% | 177.3% | |||
| TVTX | Travere Therapeutics | 1.21% | 58.85 | 0.0% | 24.7% | 54.0% | 298.4% | 284.6% | 293.6% | 230.4% |
| MIRM | Mirum Pharmaceuticals | 1.20% | 123.77 | 0.0% | 21.9% | 56.7% | 142.3% | 403.3% | 607.3% | |
| CYTK | Cytokinetics | 1.19% | 82.19 | 0.0% | 7.1% | 29.4% | 147.9% | 151.0% | 289.2% | 766.1% |
| NTRA | Natera | 1.18% | 261.91 | 0.0% | 17.3% | 14.3% | 55.9% | 434.2% | 125.0% | 2,070.8% |
| ROIV | Roivant Sciences | 1.17% | 34.07 | 0.0% | 13.6% | 57.0% | 199.1% | 244.1% | 244.1% | |
| COGT | Cogent Biosciences | 1.17% | 38.10 | 0.0% | 9.0% | 7.3% | 436.6% | 229.3% | 375.1% | |
| DNTH | Dianthus Therapeutics | 1.16% | 95.35 | 0.0% | 2.5% | 131.4% | 440.8% | 12,446.1% | 820.4% | |
| SRRK | Scholar Rock | 1.16% | 54.76 | 0.0% | 11.1% | 24.3% | 52.9% | 699.4% | 92.1% | |
| PCVX | Vaxcyte | 1.16% | 56.52 | 0.0% | 10.0% | 22.5% | 73.5% | 16.5% | 150.3% | |
| RVMD | Revolution Medicines | 1.15% | 182.08 | 0.0% | 15.6% | 128.6% | 393.3% | 594.4% | 470.1% | |
| QURE | uniQure | 1.15% | 47.51 | 0.0% | 66.5% | 98.5% | 242.8% | 327.2% | 52.3% | 544.6% |
Guidance Updates for XBI Top Holdings
| Ticker | Company | Earnings Date | Guidance Metric | Midpoint Value | % Change | Guidance Change | |
|---|---|---|---|---|---|---|---|
| TWST_5042026 | TWST | Twist Bioscience | 5/4/2026 | Q3 2026 Revenue | 114.50 Mil | 6.5% | Higher NewNew Guidance Higher than Prior Actual of 107.50 Mil for Q2 2026 |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| XBI Return | -20% | -26% | 8% | 1% | 36% | 24% | 8% |
| Peers Return | 33% | -5% | 32% | 13% | 33% | 45% | 263% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 7% | 96% |
Monthly Win Rates [3] | |||||||
| XBI Win Rate | 33% | 50% | 50% | 50% | 67% | 100% | |
| Peers Win Rate | 63% | 48% | 58% | 57% | 67% | 70% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| XBI Max Drawdown | -37% | -46% | -30% | -20% | -26% | -10% | |
| Peers Max Drawdown | -18% | -35% | -16% | -18% | -27% | -15% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: SMH, SOXX, IBB, ITA, XOP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/26/2026 (YTD)
Sharpe Ratios Compared
One measure of reward vs. risk is a Sharpe ratio. A higher ratio indicates better risk-adjusted returns. Most funds have Sharpe ratios < 1.0.
Results as of 5312026.How Low Can It Go
| Event | XBI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.9% | -9.5% |
| % Gain to Breakeven | 29.7% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -14.5% | -6.7% |
| % Gain to Breakeven | 17.0% | 7.1% |
| Time to Breakeven | 48 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -45.6% | -24.5% |
| % Gain to Breakeven | 83.8% | 32.4% |
| Time to Breakeven | 1290 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.9% | -33.7% |
| % Gain to Breakeven | 49.1% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.0% | 23.8% |
| Time to Breakeven | 351 days | 105 days |
In The Past
State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | XBI | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -24.6% | -18.8% |
| % Gain to Breakeven | 32.6% | 23.1% |
| Time to Breakeven | 147 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -22.9% | -9.5% |
| % Gain to Breakeven | 29.7% | 10.5% |
| Time to Breakeven | 47 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -45.6% | -24.5% |
| % Gain to Breakeven | 83.8% | 32.4% |
| Time to Breakeven | 1290 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -32.9% | -33.7% |
| % Gain to Breakeven | 49.1% | 50.9% |
| Time to Breakeven | 53 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -31.1% | -19.2% |
| % Gain to Breakeven | 45.0% | 23.8% |
| Time to Breakeven | 351 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -21.4% | -3.7% |
| % Gain to Breakeven | 27.2% | 3.9% |
| Time to Breakeven | 11 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -42.3% | -12.2% |
| % Gain to Breakeven | 73.2% | 13.9% |
| Time to Breakeven | 497 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -26.7% | -17.9% |
| % Gain to Breakeven | 36.5% | 21.8% |
| Time to Breakeven | 172 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -29.1% | -53.4% |
| % Gain to Breakeven | 41.0% | 114.4% |
| Time to Breakeven | 371 days | 1085 days |
In The Past
State Street SPDR S&P Biotech ETF's stock fell -24.6% during the 2025 US Tariff Shock. Such a loss loss requires a 32.6% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
Current Dip Buy Opportunities Across ETFs
ETFs currently down 5% or more from trailing 6M peaks.
| Ticker | Name | Dip % | Mkt Price | Price Date | Peak Price | Peak Date | # Days |
|---|---|---|---|---|---|---|---|
| OEF | iShares S&P 100 ETF | -5.4% | 357.57 | 6282026 | 378.10 | 6012026 | 27 |
| XLG | Invesco S&P 500 Top 50 ETF | -8.2% | 59.30 | 6282026 | 64.59 | 6012026 | 27 |
| MAGS | Roundhill Magnificent Seven ETF | -13.2% | 61.60 | 6282026 | 70.94 | 5142026 | 45 |
| QQQ | Invesco QQQ Trust, Series 1 | -5.3% | 706.52 | 6282026 | 746.16 | 6022026 | 26 |
| QQQM | Invesco NASDAQ 100 ETF | -5.3% | 290.95 | 6282026 | 307.23 | 6022026 | 26 |
| ONEQ | Fidelity Nasdaq Composite Index ETF | -6.9% | 99.38 | 6282026 | 106.70 | 6022026 | 26 |
| VUG | Vanguard Growth ETF | -8.2% | 82.76 | 6282026 | 90.19 | 6012026 | 27 |
| IWF | iShares Russell 1000 Growth ETF | -7.6% | 119.04 | 6282026 | 128.77 | 6012026 | 27 |
| IVW | iShares S&P 500 Growth ETF | -6.4% | 132.58 | 6282026 | 141.59 | 6012026 | 27 |
| SCHG | Schwab U.S. Large-Cap Growth ETF | -7.0% | 32.84 | 6282026 | 35.30 | 6012026 | 27 |
| SPYG | State Street SPDR Portfolio S&P 500 Growth ETF | -6.4% | 114.71 | 6282026 | 122.60 | 6012026 | 27 |
| VONG | Vanguard Russell 1000 Growth ETF | -7.7% | 122.12 | 6282026 | 132.35 | 6012026 | 27 |
| MGK | Vanguard Mega Cap Growth ETF | -8.4% | 84.27 | 6282026 | 91.97 | 6012026 | 27 |
| AKRE | Akre Focus ETF | -19.7% | 53.50 | 6282026 | 66.59 | 1062026 | 173 |
| SCZ | iShares MSCI EAFE Small-Cap ETF | -5.0% | 82.16 | 6282026 | 86.49 | 5312026 | 28 |
| VSS | Vanguard FTSE All-World EX-US Small-Cap Index Fund | -5.4% | 153.01 | 6282026 | 161.79 | 5112026 | 48 |
| SCHC | Schwab International Small-Cap Equity ETF | -7.4% | 47.75 | 6282026 | 51.54 | 3012026 | 119 |
| IEMG | iShares Core MSCI Emerging Markets ETF | -5.5% | 81.30 | 6282026 | 86.00 | 6222026 | 6 |
| EEM | iShares MSCI Emerging Markets ETF | -5.6% | 67.19 | 6282026 | 71.21 | 6222026 | 6 |
| FNDE | Schwab Fundamental Emerging Markets Equity ETF | -7.2% | 39.28 | 6282026 | 42.35 | 6022026 | 26 |
| EWY | iShares MSCI South Korea ETF | -10.0% | 197.28 | 6282026 | 219.20 | 6212026 | 7 |
| EWZ | iShares MSCI Brazil ETF | -16.9% | 34.67 | 6282026 | 41.73 | 4142026 | 75 |
| FXI | iShares China Large-Cap ETF | -22.5% | 31.59 | 6282026 | 40.78 | 1292026 | 150 |
| ILF | iShares Latin America 40 ETF | -11.3% | 33.81 | 6282026 | 38.10 | 4142026 | 75 |
| KWEB | KraneShares CSI China Internet ETF | -36.4% | 23.94 | 6282026 | 37.66 | 1122026 | 167 |
| SCHY | Schwab International Dividend Equity ETF | -5.9% | 31.74 | 6282026 | 33.73 | 3012026 | 119 |
| QQQI | NEOS Nasdaq 100 High Income ETF | -5.2% | 54.69 | 6282026 | 57.69 | 6022026 | 26 |
| MTUM | iShares MSCI USA Momentum Factor ETF | -5.6% | 325.74 | 6282026 | 345.22 | 6222026 | 6 |
| ARKK | ARK Innovation ETF | -6.1% | 78.13 | 6282026 | 83.21 | 1132026 | 166 |
| URA | Global X Uranium ETF | -29.5% | 43.59 | 6282026 | 61.81 | 1282026 | 151 |
| BOTZ | Global X Funds Global X Robotics & Artificial Intelligence ETF | -13.5% | 36.01 | 6282026 | 41.63 | 5132026 | 46 |
| ROBO | ROBO Global Robotics & Automation Index ETF | -9.2% | 82.00 | 6282026 | 90.34 | 6022026 | 26 |
| LIT | Global X Lithium & Battery Tech ETF | -17.1% | 75.93 | 6282026 | 91.62 | 5112026 | 48 |
| ICLN | iShares Global Clean Energy ETF | -17.9% | 19.50 | 6282026 | 23.75 | 6022026 | 26 |
| ARKQ | ARK Autonomous Technology & Robotics ETF | -14.1% | 123.60 | 6282026 | 143.82 | 5282026 | 31 |
| ARKW | ARK Next Generation Internet ETF | -9.7% | 139.22 | 6282026 | 154.18 | 6012026 | 27 |
| ARKX | ARK Space & Defense Innovation ETF | -15.4% | 31.93 | 6282026 | 37.74 | 5282026 | 31 |
| NASA | Tema Space Innovators ETF | -36.5% | 26.58 | 6282026 | 41.89 | 5272026 | 32 |
| XOVR | EntrepreneurShares Series Trust ERShares Private-Public Crossover ETF | -5.9% | 19.69 | 6282026 | 20.93 | 6162026 | 12 |
| AGIX | KraneShares Artificial Intelligence ETF | -9.3% | 44.79 | 6282026 | 49.40 | 6012026 | 27 |
| CGBL | Capital Group Core Balanced ETF | -6.2% | 34.41 | 6282026 | 36.67 | 2252026 | 123 |
| GDE | WisdomTree Efficient Gold Plus Equity Strategy Fund | -13.8% | 60.67 | 6282026 | 70.39 | 5112026 | 48 |
| RAAX | VanEck Real Assets ETF | -6.8% | 39.81 | 6282026 | 42.70 | 5112026 | 48 |
| VGT | Vanguard Information Technology ETF | -9.4% | 113.86 | 6282026 | 125.62 | 6022026 | 26 |
| XLK | State Street Technology Select Sector SPDR ETF | -8.6% | 181.11 | 6282026 | 198.21 | 6022026 | 26 |
| XLE | State Street Energy Select Sector SPDR ETF | -13.9% | 53.84 | 6282026 | 62.56 | 3292026 | 91 |
| XLC | State Street Communication Services Select Sector SPDR ETF | -11.3% | 106.18 | 6282026 | 119.70 | 2012026 | 147 |
| XLY | State Street Consumer Discretionary Select Sector SPDR ETF | -8.0% | 114.37 | 6282026 | 124.27 | 1122026 | 167 |
| XLP | State Street Consumer Staples Select Sector SPDR ETF | -5.4% | 84.71 | 6282026 | 89.51 | 3012026 | 119 |
| FXN | First Trust Energy AlphaDEX Fund | -12.4% | 20.31 | 6282026 | 23.18 | 3292026 | 91 |
| SMH | VanEck Semiconductor ETF | -8.6% | 611.61 | 6282026 | 668.91 | 6222026 | 6 |
| SOXX | iShares Semiconductor ETF | -9.9% | 589.94 | 6282026 | 655.01 | 6222026 | 6 |
| ITA | iShares U.S. Aerospace & Defense ETF | -5.4% | 236.78 | 6282026 | 250.42 | 3022026 | 118 |
| XOP | State Street SPDR S&P Oil & Gas Exploration & Production ETF | -17.8% | 154.68 | 6282026 | 188.18 | 3292026 | 91 |
| IGV | iShares Expanded Tech-Software Sector ETF | -18.4% | 88.20 | 6282026 | 108.10 | 12282025 | 182 |
| IAI | iShares U.S. Broker-Dealers & Securities Exchanges ETF | -7.3% | 175.82 | 6282026 | 189.59 | 1152026 | 164 |
| MISL | First Trust Indxx Aerospace & Defense ETF | -13.5% | 44.10 | 6282026 | 50.98 | 1192026 | 160 |
| RING | iShares MSCI Global Gold Miners ETF | -33.7% | 65.96 | 6282026 | 99.42 | 3012026 | 119 |
| SOXQ | Invesco PHLX Semiconductor ETF | -9.9% | 103.69 | 6282026 | 115.11 | 6222026 | 6 |
| BWX | State Street SPDR Bloomberg International Treasury Bond ETF | -5.3% | 21.73 | 6282026 | 22.95 | 2162026 | 132 |
| PDBC | Invesco Optimum Yield Diversified Commodity Strategy No K-1 ETF | -16.1% | 15.87 | 6282026 | 18.91 | 5122026 | 47 |
| DBC | Invesco DB Commodity Index Tracking Fund | -16.2% | 26.57 | 6282026 | 31.69 | 5122026 | 47 |
| COMT | iShares GSCI Commodity Dynamic Roll Strategy ETF | -17.3% | 30.21 | 6282026 | 36.53 | 5192026 | 40 |
| GSG | iShares GSCI Commodity | -5.8% | 30.01 | 6282026 | 31.85 | 3182026 | 102 |
| BCI | abrdn Bloomberg All Commodity Strategy K-1 Free ETF | -14.0% | 22.29 | 6282026 | 25.91 | 5122026 | 47 |
| FTGC | First Trust Global Tactical Commodity Strategy Fund | -11.9% | 26.91 | 6282026 | 30.53 | 5122026 | 47 |
| HGER | Harbor Commodity All-Weather Strategy ETF | -12.6% | 29.25 | 6282026 | 33.47 | 5122026 | 47 |
| GLD | SPDR Gold Trust | -24.7% | 373.63 | 6282026 | 495.90 | 1292026 | 150 |
| IAU | iShares Gold Trust | -24.6% | 76.56 | 6282026 | 101.57 | 1292026 | 150 |
| GLDM | SPDR Gold MiniShares Trust | -24.5% | 80.61 | 6282026 | 106.77 | 1292026 | 150 |
| SGOL | ETFS Physical Swiss Gold Shares | -13.1% | 44.66 | 6282026 | 51.41 | 1292026 | 150 |
| BAR | Direxion Daily Gold Bull 3X Shares | -16.6% | 44.34 | 6282026 | 53.16 | 1292026 | 150 |
| SLV | iShares Silver Trust | -49.5% | 53.28 | 6282026 | 105.60 | 1282026 | 151 |
| SIVR | ETFS Physical Silver Shares Trust ETF | -24.8% | 83.39 | 6282026 | 110.87 | 1282026 | 151 |
| PPLT | ETFS Physical Platinum Shares | -41.4% | 14.77 | 6282026 | 25.23 | 1252026 | 154 |
| CPER | United States Copper Index Fund ETV | -13.9% | 33.33 | 6282026 | 38.71 | 1292026 | 150 |
| PALL | ETFS Physical Palladium Shares | -40.7% | 22.04 | 6282026 | 37.18 | 1282026 | 151 |
| USO | United States Oil Fund LP | -31.0% | 105.48 | 6282026 | 152.96 | 5192026 | 40 |
| UNG | United States Natural Gas Fund LP | -29.8% | 11.87 | 6282026 | 16.90 | 2012026 | 147 |
| BNO | United States Brent Oil Fund LP ETV | -7.1% | 55.85 | 6282026 | 60.13 | 5042026 | 55 |
| IBIT | iShares Bitcoin Trust ETF | -38.9% | 33.85 | 6282026 | 55.44 | 1142026 | 165 |
| FBTC | Fidelity Wise Origin Bitcoin Fund | -38.9% | 51.98 | 6282026 | 85.12 | 1142026 | 165 |
| GBTC | Grayscale Bitcoin Trust ETF | -19.0% | 61.84 | 6282026 | 76.31 | 1142026 | 165 |
| ETHA | iShares Ethereum Trust ETF | -53.5% | 11.89 | 6282026 | 25.59 | 1142026 | 165 |
ETF Fund Flows
Largest fund inflows and outflows across ETFs, with the asset-allocation rotation they imply.
Asset allocation rotation · Past month
- Equity ETFs drew the largest net inflows (+$66.6B), followed by Bond (+$20.3B), while Commodity (−$6.2B) and Crypto (−$4.6B) saw the largest outflows.
- Within the mix, money rotated into US Large Cap Core (+$25.7B) and out of Gold (−$5.7B).
- Relative to fund size, ARKQ drew the largest inflow (+54.0% of AUM) and VLUE the largest outflow (−35.2%).
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | IVV | iShares Core S&P 500 ETF | +$45.78B | +5.4% |
| 2 | SPY | State Street SPDR S&P 500 ETF Trust | +$14.76B | +1.9% |
| 3 | DRAM | Roundhill Memory ETF | +$7.72B | +45.8% |
| 4 | SPYM | State Street SPDR Portfolio S&P 500 ETF | +$7.19B | +4.8% |
| 5 | VONG | Vanguard Russell 1000 Growth ETF | +$4.94B | +11.1% |
| 6 | QQQM | Invesco NASDAQ 100 ETF | +$4.74B | +4.8% |
| 7 | VHT | Vanguard Health Care ETF | +$4.39B | +26.1% ⚠ |
| 8 | SGOV | iShares 0-3 Month Treasury Bond ETF | +$4.14B | +4.4% |
| 9 | SOXX | iShares Semiconductor ETF | +$4.03B | +9.5% |
| 10 | VONV | Vanguard Russell 1000 Value ETF | +$3.96B | +20.0% |
| # | Ticker | Name | Net flow | % of AUM |
|---|---|---|---|---|
| 1 | VOO | Vanguard S&P 500 ETF | -$41.52B | -4.2% |
| 2 | EFV | iShares MSCI EAFE Value ETF | -$5.56B | -22.6% |
| 3 | VLUE | iShares MSCI USA Value Factor ETF | -$5.05B | -35.2% |
| 4 | GLD | SPDR Gold Shares | -$3.69B | -2.6% |
| 5 | IBIT | iShares Bitcoin Trust ETF | -$3.17B | -6.5% |
| 6 | IAGG | iShares Core International Aggregate Bond ETF | -$2.79B | -25.7% |
| 7 | TLT | iShares 20+ Year Treasury Bond ETF | -$2.41B | -5.9% |
| 8 | QUAL | iShares MSCI USA Quality Factor ETF | -$2.05B | -4.5% |
| 9 | IAU | iShares Gold Trust | -$1.79B | -2.7% |
| 10 | IWM | iShares Russell 2000 ETF | -$1.66B | -2.0% |
Largest ETF fund flows across ~2559 funds (min AUM $100M). Net creations/redemptions; leveraged & inverse ETFs excluded. A ⚠ marks a day excluded as a suspected data error.
About XBI
| Holdings Count: 157Expense Ratio: 0.35%Inception Date: 2006-01-31 | State Street SPDR S&P Biotech ETFSPDR Series Trust - State Street SPDR S&P Biotech ETF is an exchange traded fund launched by State Street Global Advisors, Inc. The fund is managed by SSGA Funds Management, Inc. It invests in public equity markets of the United States. It invests in stocks of companies operating across health care, pharmaceuticals, biotechnology and life sciences sectors. The fund invests in growth and value stocks of companies across diversified market capitalization. It seeks to track the performance of the S&P Biotechnology Select Industry Index, by using representative sampling technique. SPDR Series Trust - State Street SPDR S&P Biotech ETF was formed on January 31, 2006 and is domiciled in the United States.Asset Class: Equity | ETF Website |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| XBI Ignored The Market's Downturn | 06/27/2026 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Profile
| Median | |
|---|---|
| Name | |
| Asset Class | - |
| AUM ($ Bil) | 12.2 |
| Expense Ratio | 0.35% |
| 10-D Avg Volume (Mil) | 6.47 |
| Latest Day Volume (Mil) | 7.46 |
| Holdings Count | 50 |
| Inception Date | - |
Fundamentals
| Median | |
|---|---|
| Name | |
| Net Asset Value | - |
| Premium/Discount | -0.0% |
| Distribution Yield | 0.2% |
| Sales Yield | 10.5% |
| Earnings Yield | 2.2% |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.